Skip to the page

Data / Drug companies / Lannett Company, Inc.

Lannett Company, Inc.: 151 products in the FDA NDC directory, labeler code 0527

Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).

Lannett Company, Inc. (labeler code 0527) lists 151 products in the FDA National Drug Code Directory, covering 50 finished drugs by generic name. By type: 151 prescription drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on January 12, 2026.

The request: Watch Lannett Company, Inc. (FDA labeler code 0527): each new product listing and each discontinued product. $10 of work on sign-up, no card.

SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.

Labeler code
0527
Products in commercial distribution
151
Packages
225
Finished drugs by generic name
50
Prescription products
151
Over the counter products
0
Controlled substance products
Schedule II 52, Schedule III 2, Schedule IV 2
Flagged as original packager
129 of 129 products that carry the flag
Started marketing in the last 12 months
1
Earliest marketing start
September 30, 1974
openFDA record search
api.fda.gov

Products by marketing category

Share of the company's products in commercial distribution.

Marketing categoryProductsShare
Generic drugs (ANDA)12784.1%
Authorized generics (NDA)1811.9%
New drug applications (NDA)64%

Products by type

TypeProductsShare
Prescription drugs151100%

Drugs it lists

Finished drugs by generic name, with how many companies list each.

Dosage forms

Dosage formProductsShare
Tablet4328.5%
Capsule, extended release3019.9%
Capsule2516.6%
Tablet, film coated1912.6%
Tablet, extended release74.6%
Tablet, coated53.3%
Tablet, orally disintegrating42.6%
Solution32%
Tablet, film coated, extended release21.3%
Spray21.3%
Tablet, delayed release21.3%
Powder21.3%

Pharmacologic classes

FDA established pharmacologic classes of its products.

Newest products

By marketing start date.

ProductProduct NDCDosage formMarketing categoryMarketing start
Fluticasone Propionate and Salmeterol0527-6010PowderGeneric drugs (ANDA)January 12, 2026
Famotidine0527-5190Powder, for suspensionGeneric drugs (ANDA)June 2, 2025
Fluticasone Propionate and Salmeterol0527-6011PowderGeneric drugs (ANDA)November 29, 2024
Metadate cd0527-6584Capsule, extended releaseNew drug applications (NDA)February 22, 2024
Metadate cd0527-6583Capsule, extended releaseNew drug applications (NDA)February 22, 2024
Metadate cd0527-6582Capsule, extended releaseNew drug applications (NDA)February 22, 2024
Metadate cd0527-6581Capsule, extended releaseNew drug applications (NDA)February 22, 2024
Metadate cd0527-6580Capsule, extended releaseNew drug applications (NDA)February 22, 2024
Metadate cd0527-6579Capsule, extended releaseNew drug applications (NDA)February 22, 2024
Prazosin0527-4182CapsuleGeneric drugs (ANDA)January 3, 2024
Prazosin0527-4181CapsuleGeneric drugs (ANDA)January 3, 2024
Prazosin0527-4180CapsuleGeneric drugs (ANDA)January 3, 2024
Lisdexamfetamine Dimesylate0527-4667CapsuleGeneric drugs (ANDA)August 25, 2023
Lisdexamfetamine Dimesylate0527-4666CapsuleGeneric drugs (ANDA)August 25, 2023
Lisdexamfetamine Dimesylate0527-4665CapsuleGeneric drugs (ANDA)August 25, 2023
Lisdexamfetamine Dimesylate0527-4664CapsuleGeneric drugs (ANDA)August 25, 2023
Lisdexamfetamine Dimesylate0527-4663CapsuleGeneric drugs (ANDA)August 25, 2023
Lisdexamfetamine Dimesylate0527-4662CapsuleGeneric drugs (ANDA)August 25, 2023
Lisdexamfetamine Dimesylate0527-4661CapsuleGeneric drugs (ANDA)August 25, 2023
Sevoflurane0527-6123LiquidGeneric drugs (ANDA)August 18, 2023
Oseltamivir Phosphate0527-5137SuspensionGeneric drugs (ANDA)July 13, 2023
Mesalamine0527-3012Tablet, delayed releaseGeneric drugs (ANDA)June 3, 2023
Olanzapine0527-3164Tablet, orally disintegratingGeneric drugs (ANDA)May 30, 2023
Olanzapine0527-3163Tablet, orally disintegratingGeneric drugs (ANDA)May 30, 2023
Olanzapine0527-3162Tablet, orally disintegratingGeneric drugs (ANDA)May 30, 2023

CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.